- Report
- March 2024
- 199 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- September 2023
- 110 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Report
- April 2024
- 194 Pages
Global
From €4778EUR$4,950USD£4,098GBP
- Report
- November 2023
- 144 Pages
Global
From €2412EUR$2,499USD£2,069GBP
- Report
- November 2023
- 181 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- March 2022
- 300 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- October 2020
Global
From €3861EUR$4,000USD£3,312GBP
- Report
- April 2023
- 113 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- January 2024
- 105 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- January 2022
- 83 Pages
Global
From €3200EUR$3,552USD£2,841GBP
- Report
- February 2024
- 178 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- May 2023
- 147 Pages
Global
From €5790EUR$5,999USD£4,967GBP
The Genitourinary Drug market is a subset of the pharmaceutical industry that focuses on drugs used to treat urological disorders. These drugs are used to treat a variety of conditions, including urinary tract infections, bladder control issues, kidney stones, and prostate enlargement. Genitourinary drugs are also used to treat erectile dysfunction, infertility, and other sexual health issues. These drugs are typically prescribed by urologists and other healthcare professionals.
The Genitourinary Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, AstraZeneca, Sanofi, and Bayer. Other companies in the market include Allergan, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more
